Miracor Medical SA, an Awans, Belgium-based provider of innovative solutions for the treatment of severe cardiac diseases, raised the final tranche of its Series D financing round, which was closed at €30M.
The round was led by Ming Capital (Shenzhen, China) and co-led by a strategic investor. Participating new investors include Belgian alternative investment fund Quest for Growth, and participating existing investors include Ming Capital, SFPI and Meusinvest. The technical and clinical research programs of Miracor are also supported by a financing program of the DGO6 (Walloon Government).
The company intends to use the funds to further develop and commercialize the PiCSO® Impulse System.
Led by Olivier Delporte, CEO, Miracor Medical provides innovative solutions for the treatment of severe cardiac diseases, aiming to improve short and long-term clinical outcomes and reduce associated cost. The company develops the PiCSO Impulse System, a coronary sinus intervention designed to reduce infarct size, improve cardiac function and potentially reduce the onset of heart failure following acute myocardial infarction. The therapy is provided during the PCI (Percutaneous Coronary Intervention) in patients enduring acute myocardial infarct (AMI).